However, even in NSCLC patients with high PD-L1 expression who would benefit from anti-PD-1 or anti-PD-L1 antibodies, only approximately half of them achieve long-term responses to immune checkpoint inhibitors [9,10,11,12,13,14,15]. Here, CD274 is linked to non-small cell lung carcinoma.